The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12544342 B1

Date of Patent:

Feb. 10, 2026

Filed:

Aug. 04, 2023

Pharmaceutical composition containing taxane nanoaggregates and use thereof

Applicants:

Fulgent Pharma, Llc, Temple City, CA (US);

Anp Technologies, Inc., Newark, DE (US);

Inventors:

Ray Yin, El Monte, CA (US);

Jing Pan, El Monte, CA (US);

Yubei Zhang, El Monte, CA (US);

Bingsen Zhou, El Monte, CA (US);

Yun Yen, El Monte, CA (US);

Li Wang, El Monte, CA (US);

Lin Wang, El Monte, CA (US);

Yilong Zhang, El Monte, CA (US);

Ming Hseih, El Monte, CA (US);

Assignee:

Fulgent Genetics, Inc., El Monte, CA (US);

Attorney:

Greenberg Traurig, LLP

Primary Examiner:

Michael G Hartley

Assistant Examiner:

Jagadishwar R Samala

Int. Cl.

CPC ...

A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01);

U.S. Cl.

CPC ...

A61K 9/5146 (2013.01); A61K 31/337 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01);

Abstract

This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate. This invention is further directed to a method for treating a disease including cancer using the pharmaceutical composition disclosed herein.

Find Patent Forward Citations